Clicky

Health

Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19
440 386 Robert

GENEVA, SWITZERLAND / ACCESSWIRE / April 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (“ Relief “), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today…

  • Robert
  • 0
  • 0

Moderna Finalizes Strategic Partnership with Australian Government
1200 277 Tori

On-shore manufacturing facility based in Melbourne, Australia, expected to produce up to 100 million mRNA respiratory vaccine doses annually CAMBRIDGE, MA / ACCESSWIRE / March 23, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering…

  • Tori
  • 0
  • 0

Health Canada Authorizes Moderna’s COVID-19 Vaccine in Children (6-11 Years)
1200 277 Merci

CAMBRIDGE, MA / ACCESSWIRE / March 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Health Canada has approved the use of Moderna’s mRNA COVID-19…

  • Merci
  • 0
  • 0

Assistance for Long COVID Sufferers Targeted by Health Advance, Inc
335 434 Tori

NEW YORK, NY / ACCESSWIRE / March 17, 2022 / Health Advance, Inc (OTC PINK:HADV) www.HealthAdvanceGroup.com is launching a joint venture to supply new treatment options for the growing number of people internationally who are…

  • Tori
  • 0
  • 0

Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19
320 110 Merci

HAMILTON, BERMUDA / ACCESSWIRE / March 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its affiliate, Altamira Medica, has received the…

  • Merci
  • 0
  • 0

Halberd’s COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant
146 37 Merci

JACKSON CENTER, PA / ACCESSWIRE / March 1, 2022 / Halberd Corporation’s (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding capability to the SARS-CoV-2 Omicron variant disease antigen. The Halberd antibody was tested against…

  • Merci
  • 0
  • 0

Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
1200 277 Merci

Endorsement to proceed given by the independent Data and Safety Monitoring Board based on preliminary Phase 2 safety and tolerability data Moderna expects to enroll approximately 34,000 participants in multiple countries RSV causes severe disease…

  • Merci
  • 0
  • 0

Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates
1200 277 Todd

Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29 Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29…

  • Todd
  • 0
  • 0

Therapeutic Goods Administration of Australia Authorizes Moderna’s Covid-19 Vaccine in Children (6-11 Years)
1200 277 Todd

CAMBRIDGE, MA / ACCESSWIRE / February 16, 2022 / Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional…

  • Todd
  • 0
  • 0